204 related articles for article (PubMed ID: 26982381)
1. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome.
Rahman A; Kittikulsuth W; Fujisawa Y; Sufiun A; Rafiq K; Hitomi H; Nakano D; Sohara E; Uchida S; Nishiyama A
J Hypertens; 2016 May; 34(5):893-906. PubMed ID: 26982381
[TBL] [Abstract][Full Text] [Related]
2. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.
Takeshige Y; Fujisawa Y; Rahman A; Kittikulsuth W; Nakano D; Mori H; Masaki T; Ohmori K; Kohno M; Ogata H; Nishiyama A
Hypertens Res; 2016 Jun; 39(6):415-22. PubMed ID: 26818652
[TBL] [Abstract][Full Text] [Related]
3. Novel mechanism for disrupted circadian blood pressure rhythm in a rat model of metabolic syndrome--the critical role of angiotensin II.
Sueta D; Kataoka K; Koibuchi N; Toyama K; Uekawa K; Katayama T; Mingjie M; Nakagawa T; Waki H; Maeda M; Yasuda O; Matsui K; Ogawa H; Kim-Mitsuyama S
J Am Heart Assoc; 2013 Apr; 2(3):e000035. PubMed ID: 23629805
[TBL] [Abstract][Full Text] [Related]
4. Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats.
Rahman A; Fujisawa Y; Nakano D; Hitomi H; Nishiyama A
Clin Exp Pharmacol Physiol; 2017 Apr; 44(4):522-525. PubMed ID: 28063156
[TBL] [Abstract][Full Text] [Related]
5. Long-term renal denervation normalizes disrupted blood pressure circadian rhythm and ameliorates cardiovascular injury in a rat model of metabolic syndrome.
Katayama T; Sueta D; Kataoka K; Hasegawa Y; Koibuchi N; Toyama K; Uekawa K; Mingjie M; Nakagawa T; Maeda M; Ogawa H; Kim-Mitsuyama S
J Am Heart Assoc; 2013 Aug; 2(4):e000197. PubMed ID: 23974905
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity.
Sueta D; Koibuchi N; Hasegawa Y; Toyama K; Uekawa K; Katayama T; Ma M; Nakagawa T; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2014 Dec; 27(12):1464-71. PubMed ID: 24871627
[TBL] [Abstract][Full Text] [Related]
7. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension.
Uzu T; Kimura G
Circulation; 1999 Oct; 100(15):1635-8. PubMed ID: 10517735
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic β-cells in obese type 2 diabetic db/db mice.
Okauchi S; Shimoda M; Obata A; Kimura T; Hirukawa H; Kohara K; Mune T; Kaku K; Kaneto H
Biochem Biophys Res Commun; 2016 Feb; 470(3):772-782. PubMed ID: 26505796
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats.
Masuda T; Ohara K; Vallon V; Nagata D
Am J Physiol Renal Physiol; 2022 Sep; 323(3):F361-F369. PubMed ID: 35900341
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension.
Dussol B; Moussi-Frances J; Morange S; Somma-Delpero C; Mundler O; Berland Y
Nephrol Dial Transplant; 2005 Feb; 20(2):349-53. PubMed ID: 15615808
[TBL] [Abstract][Full Text] [Related]
11. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome.
Nakagami H; Pang Z; Shimosato T; Moritani T; Kurinami H; Koriyama H; Tenma A; Shimamura M; Morishita R
Hypertens Res; 2014 Jul; 37(7):629-35. PubMed ID: 24621463
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials.
Sakai S; Kaku K; Seino Y; Inagaki N; Haneda M; Sasaki T; Fukatsu A; Kakiuchi H; Samukawa Y
Clin Ther; 2016 Apr; 38(4):843-862.e9. PubMed ID: 27021608
[TBL] [Abstract][Full Text] [Related]
13. Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study).
Hashimoto-Kameda R; Cho KY; Nomoto H; Nakamura A; Omori K; Nagai S; Edagawa S; Kawata S; Takeuchi J; Kameda H; Kurihara Y; Aoki S; Atsumi T; Miyoshi H;
Diabetes Res Clin Pract; 2021 Oct; 180():109069. PubMed ID: 34563585
[TBL] [Abstract][Full Text] [Related]
14. Failure to confirm a sodium-glucose cotransporter 2 inhibitor-induced hematopoietic effect in non-diabetic rats with renal anemia.
Yamazaki D; Konishi Y; Morikawa T; Kobara H; Masaki T; Hitomi H; Osafune K; Nakano D; Kittikulsuth W; Nishiyama A
J Diabetes Investig; 2020 Jul; 11(4):834-843. PubMed ID: 31880858
[TBL] [Abstract][Full Text] [Related]
15. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
[TBL] [Abstract][Full Text] [Related]
16. Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats.
Wienen W; Schierok HJ
J Renin Angiotensin Aldosterone Syst; 2001 Jun; 2(2):123-8. PubMed ID: 11881111
[TBL] [Abstract][Full Text] [Related]
17. Luseogliflozin for the treatment of type 2 diabetes.
Seino Y
Expert Opin Pharmacother; 2014 Dec; 15(18):2741-9. PubMed ID: 25359155
[TBL] [Abstract][Full Text] [Related]
18. Acute blood pressure and urinary responses to single dose combinations of captopril and diuretics in conscious spontaneously hypertensive rats.
Chiu PJ; Vemulapalli S; Barnett A
J Pharm Pharmacol; 1985 Feb; 37(2):105-9. PubMed ID: 2858541
[TBL] [Abstract][Full Text] [Related]
19. Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.
Yabe D; Hamamoto Y; Seino Y; Kuwata H; Kurose T; Seino Y
Expert Opin Drug Saf; 2017 Oct; 16(10):1211-1218. PubMed ID: 28741382
[TBL] [Abstract][Full Text] [Related]
20. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
